Esperion (ESPR +2.8%) announces
that NEXLIZET (bempedoic acid and ezetimibe) tablets, the first
approved oral, non-statin LDL-Cholesterol (LDL-C) lowering combination
medicine is now available in U.S. pharmacies.
Additionally, NEXLIZET is introduced with broad
payer coverage for both eligible insured patients and those with
Medicare Part D at an affordable price and co-pay.
NEXLIZET is indicated as an adjunct to diet and
maximally tolerated statin therapy for the treatment of adults with
heterozygous familial hypercholesterolemia or established
atherosclerotic cardiovascular disease who require additional lowering
of LDL-C.
https://seekingalpha.com/news/3580472-esperions-nexlizet-tablets-for-ldl-cholesterol-lowering-now-available-in-u-s
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.